从浪费到价值:Xpert MTB/XDR对受污染液体培养物的诊断准确性,以挽救耐药结核病的检测。

IF 6.1 2区 医学 Q1 MICROBIOLOGY
Yonas Ghebrekristos, Erick Auma, Zama Mahlobo, Rouxjeane Venter, Natalie Beylis, Jay Achar, Brigitta Derendinger, Sarishna Singh, Megan Burger, Christoffel Opperman, Robin Warren, Grant Theron
{"title":"从浪费到价值:Xpert MTB/XDR对受污染液体培养物的诊断准确性,以挽救耐药结核病的检测。","authors":"Yonas Ghebrekristos, Erick Auma, Zama Mahlobo, Rouxjeane Venter, Natalie Beylis, Jay Achar, Brigitta Derendinger, Sarishna Singh, Megan Burger, Christoffel Opperman, Robin Warren, Grant Theron","doi":"10.1128/jcm.00580-25","DOIUrl":null,"url":null,"abstract":"<p><p>Mycobacterium Growth Indicator Tube (MGIT) 960 culture is critical for tuberculosis (TB) drug susceptibility testing (DST) but is vulnerable to contamination. We evaluated the accuracy of Xpert MTB/XDR, a molecular DST for isoniazid, fluoroquinolone, amikacin, and ethionamide, on to-be-discarded contaminated growth. Xpert MTB/XDR was applied to acid-fast-bacilli-negative, contaminated cultures from sputum from people with rifampicin-resistant TB when Xpert MTB/XDR on sputum was unsuccessful (not resistant or susceptible for all drugs), either at diagnosis (Cohort A) or during treatment monitoring (Cohort B). Future DSTs within 3 months served as a reference standard. We determined potential care cascade improvements. In Cohort A, 10% (66/650) of people had a contaminated culture; 89% (59/66) of contaminated growths were Xpert MTB/XDR TB-positive. Sensitivity and specificity for isoniazid, fluoroquinolone, amikacin, and ethionamide resistance were 100% (95% confidence interval [CI] 85, 100) and 100% (79, 100); 100% (59, 100) and 100% (89, 100); 100% (16, 100) and 100% (91, 100); and 100% (72, 100) and 96% (78, 100), respectively. In Cohort B, 22% (28/129) of people with a contaminated culture were Xpert MTB/XDR TB-positive. Of these, 57% (16/28), 7% (2/28), and 43% (12/28) were isoniazid-, fluoroquinolone-, and ethionamide-resistant (in two, one, and four people, respectively, this would be the first resistant result). In both cohorts, time-to-DST could improve by a median (IQR) of 22 (12-42) days. Xpert MTB/XDR on contaminated MGIT960 cultures had high sensitivity and specificity for DST. This approach could mitigate culture contamination's negative effects and improve gaps in the drug-resistant TB diagnostic cascade.</p><p><strong>Importance: </strong>Culture contamination is a common impediment to drug susceptibility testing for tuberculosis, the single biggest infectious cause of death globally. Xpert MTB/XDR is a World Health Organization-recommended rapid molecular test for second-line drug resistance. We evaluated Xpert MTB/XDR on contaminated liquid culture growth that would otherwise be discarded, with the people who provided these specimens potentially lost from care cascades. By applying Xpert MTB/XDR to contaminated growth in a high-volume programmatic laboratory, we found the number of people who had second-line DST improved, as did the number of resistant cases diagnosed and time to diagnosis. Furthermore, DST information was generated in people who otherwise would have had none. This approach can therefore reduce the effect of culture contamination on tuberculosis DST, permitting earlier diagnosis and effective treatment initiation and potentially ultimately contributing to improving clinical outcomes and reducing transmission of drug-resistant TB.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0058025"},"PeriodicalIF":6.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Waste to worth: diagnostic accuracy of Xpert MTB/XDR on contaminated liquid cultures to salvage the detection of drug-resistant tuberculosis.\",\"authors\":\"Yonas Ghebrekristos, Erick Auma, Zama Mahlobo, Rouxjeane Venter, Natalie Beylis, Jay Achar, Brigitta Derendinger, Sarishna Singh, Megan Burger, Christoffel Opperman, Robin Warren, Grant Theron\",\"doi\":\"10.1128/jcm.00580-25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Mycobacterium Growth Indicator Tube (MGIT) 960 culture is critical for tuberculosis (TB) drug susceptibility testing (DST) but is vulnerable to contamination. We evaluated the accuracy of Xpert MTB/XDR, a molecular DST for isoniazid, fluoroquinolone, amikacin, and ethionamide, on to-be-discarded contaminated growth. Xpert MTB/XDR was applied to acid-fast-bacilli-negative, contaminated cultures from sputum from people with rifampicin-resistant TB when Xpert MTB/XDR on sputum was unsuccessful (not resistant or susceptible for all drugs), either at diagnosis (Cohort A) or during treatment monitoring (Cohort B). Future DSTs within 3 months served as a reference standard. We determined potential care cascade improvements. In Cohort A, 10% (66/650) of people had a contaminated culture; 89% (59/66) of contaminated growths were Xpert MTB/XDR TB-positive. Sensitivity and specificity for isoniazid, fluoroquinolone, amikacin, and ethionamide resistance were 100% (95% confidence interval [CI] 85, 100) and 100% (79, 100); 100% (59, 100) and 100% (89, 100); 100% (16, 100) and 100% (91, 100); and 100% (72, 100) and 96% (78, 100), respectively. In Cohort B, 22% (28/129) of people with a contaminated culture were Xpert MTB/XDR TB-positive. Of these, 57% (16/28), 7% (2/28), and 43% (12/28) were isoniazid-, fluoroquinolone-, and ethionamide-resistant (in two, one, and four people, respectively, this would be the first resistant result). In both cohorts, time-to-DST could improve by a median (IQR) of 22 (12-42) days. Xpert MTB/XDR on contaminated MGIT960 cultures had high sensitivity and specificity for DST. This approach could mitigate culture contamination's negative effects and improve gaps in the drug-resistant TB diagnostic cascade.</p><p><strong>Importance: </strong>Culture contamination is a common impediment to drug susceptibility testing for tuberculosis, the single biggest infectious cause of death globally. Xpert MTB/XDR is a World Health Organization-recommended rapid molecular test for second-line drug resistance. We evaluated Xpert MTB/XDR on contaminated liquid culture growth that would otherwise be discarded, with the people who provided these specimens potentially lost from care cascades. By applying Xpert MTB/XDR to contaminated growth in a high-volume programmatic laboratory, we found the number of people who had second-line DST improved, as did the number of resistant cases diagnosed and time to diagnosis. Furthermore, DST information was generated in people who otherwise would have had none. This approach can therefore reduce the effect of culture contamination on tuberculosis DST, permitting earlier diagnosis and effective treatment initiation and potentially ultimately contributing to improving clinical outcomes and reducing transmission of drug-resistant TB.</p>\",\"PeriodicalId\":15511,\"journal\":{\"name\":\"Journal of Clinical Microbiology\",\"volume\":\" \",\"pages\":\"e0058025\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1128/jcm.00580-25\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/jcm.00580-25","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

分枝杆菌生长指示管(MGIT) 960培养对结核病(TB)药敏试验(DST)至关重要,但容易受到污染。我们评估了Xpert MTB/XDR(异烟肼、氟喹诺酮、阿米卡星和乙酰胺的分子DST)在即将丢弃的污染生长物上的准确性。当在诊断时(队列A)或治疗监测期间(队列B)痰液中Xpert MTB/XDR检测不成功(对所有药物均不耐药或敏感)时,将Xpert MTB/XDR应用于利福平耐药结核病患者痰液中的抗酸杆菌阴性污染培养物。未来3个月内的DSTs作为参考标准。我们确定了潜在的护理级联改进。在A队列中,10%(66/650)的人有受污染的培养;89%(59/66)的污染生长为Xpert MTB/XDR结核阳性。异烟肼、氟喹诺酮、阿米卡星和乙硫酰胺耐药的敏感性和特异性分别为100%(95%可信区间[CI] 85、100)和100%(79、100);100%(59, 100)和100% (89,100);100%(16,100)和100% (91,100);100%(72,100)和96%(78,100)。在队列B中,22%(28/129)受污染培养的人是Xpert MTB/XDR结核病阳性。其中,57%(16/28)、7%(2/28)和43%(12/28)对异烟肼、氟喹诺酮和乙酰胺耐药(分别为2人、1人和4人,这将是第一次耐药结果)。在这两个队列中,到dst的时间可以改善22(12-42)天的中位数(IQR)。Xpert MTB/XDR对MGIT960污染培养物检测DST具有较高的敏感性和特异性。这种方法可以减轻培养物污染的负面影响,并改善耐药结核病诊断级联中的空白。重要性:培养物污染是结核病药敏试验的常见障碍,结核病是全球最大的单一传染性死亡原因。Xpert MTB/XDR是世界卫生组织推荐的用于二线耐药性的快速分子检测。我们评估了Xpert MTB/XDR对受污染的液体培养物的影响,否则这些液体培养物将被丢弃,提供这些标本的人可能会因护理级联而丢失。通过将Xpert MTB/XDR应用于高容量程序化实验室的污染生长,我们发现接受二线DST的人数有所增加,诊断出的耐药病例数量和诊断时间也有所增加。此外,DST信息是在那些本来没有DST的人身上产生的。因此,这种方法可以减少培养物污染对结核病DST的影响,允许早期诊断和有效治疗,并可能最终有助于改善临床结果和减少耐药结核病的传播。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Waste to worth: diagnostic accuracy of Xpert MTB/XDR on contaminated liquid cultures to salvage the detection of drug-resistant tuberculosis.

Mycobacterium Growth Indicator Tube (MGIT) 960 culture is critical for tuberculosis (TB) drug susceptibility testing (DST) but is vulnerable to contamination. We evaluated the accuracy of Xpert MTB/XDR, a molecular DST for isoniazid, fluoroquinolone, amikacin, and ethionamide, on to-be-discarded contaminated growth. Xpert MTB/XDR was applied to acid-fast-bacilli-negative, contaminated cultures from sputum from people with rifampicin-resistant TB when Xpert MTB/XDR on sputum was unsuccessful (not resistant or susceptible for all drugs), either at diagnosis (Cohort A) or during treatment monitoring (Cohort B). Future DSTs within 3 months served as a reference standard. We determined potential care cascade improvements. In Cohort A, 10% (66/650) of people had a contaminated culture; 89% (59/66) of contaminated growths were Xpert MTB/XDR TB-positive. Sensitivity and specificity for isoniazid, fluoroquinolone, amikacin, and ethionamide resistance were 100% (95% confidence interval [CI] 85, 100) and 100% (79, 100); 100% (59, 100) and 100% (89, 100); 100% (16, 100) and 100% (91, 100); and 100% (72, 100) and 96% (78, 100), respectively. In Cohort B, 22% (28/129) of people with a contaminated culture were Xpert MTB/XDR TB-positive. Of these, 57% (16/28), 7% (2/28), and 43% (12/28) were isoniazid-, fluoroquinolone-, and ethionamide-resistant (in two, one, and four people, respectively, this would be the first resistant result). In both cohorts, time-to-DST could improve by a median (IQR) of 22 (12-42) days. Xpert MTB/XDR on contaminated MGIT960 cultures had high sensitivity and specificity for DST. This approach could mitigate culture contamination's negative effects and improve gaps in the drug-resistant TB diagnostic cascade.

Importance: Culture contamination is a common impediment to drug susceptibility testing for tuberculosis, the single biggest infectious cause of death globally. Xpert MTB/XDR is a World Health Organization-recommended rapid molecular test for second-line drug resistance. We evaluated Xpert MTB/XDR on contaminated liquid culture growth that would otherwise be discarded, with the people who provided these specimens potentially lost from care cascades. By applying Xpert MTB/XDR to contaminated growth in a high-volume programmatic laboratory, we found the number of people who had second-line DST improved, as did the number of resistant cases diagnosed and time to diagnosis. Furthermore, DST information was generated in people who otherwise would have had none. This approach can therefore reduce the effect of culture contamination on tuberculosis DST, permitting earlier diagnosis and effective treatment initiation and potentially ultimately contributing to improving clinical outcomes and reducing transmission of drug-resistant TB.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Clinical Microbiology
Journal of Clinical Microbiology 医学-微生物学
CiteScore
17.10
自引率
4.30%
发文量
347
审稿时长
3 months
期刊介绍: The Journal of Clinical Microbiology® disseminates the latest research concerning the laboratory diagnosis of human and animal infections, along with the laboratory's role in epidemiology and the management of infectious diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信